Crescent Biopharma, Inc.
Price Action
Technical Summary
EMERGING TRENDCrescent Biopharma, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is moderate (RS Rating: 78), indicating performance broadly in line with the market. Earnings growth of 10% provides fundamental context to the price action. Investors should exercise caution due to high volatility (79% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $17.90 | +0.56% | ABOVE |
| 50 SMA | $19.65 | -8.38% | BELOW |
| 100 SMA | $16.39 | +9.85% | ABOVE |
| 150 SMA | $15.08 | +19.36% | ABOVE |
| 200 SMA | $14.42 | +24.82% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is CBIO in an uptrend right now?
CBIO has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is CBIO overbought or oversold?
CBIO's RSI (14) is 50. The stock is in neutral territory, neither overbought nor oversold.
Is CBIO outperforming the market?
CBIO has a Relative Strength (RS) Rating of 78 out of 99. CBIO is performing about average compared to the market.
Where is CBIO in its 52-week range?
CBIO is trading at $18.00, which is 66% of its 52-week high ($27.41) and 50% above its 52-week low ($8.72).
How volatile is CBIO?
CBIO has a Beta of 0.72 and 52-week volatility of 79%. It's less volatile than the S&P 500 - generally more stable.